Clinical trials
Phase 1/2 Multiple Myeloma trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 14 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 30 |
| Unknown status | 23 |
| Not yet recruiting | 5 |
| Terminated | 3 |
| Completed | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chongqing Precision Biotech Co., Ltd | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| The First Affiliated Hospital of Soochow University | 3 |
| Xuzhou Medical University | 3 |
| Chinese PLA General Hospital | 2 |
| Essen Biotech | 2 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| Shenzhen University General Hospital | 2 |
| Teva Branded Pharmaceutical Products R&D LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 63 |
| Recurrence | 7 |
| Neoplasms, Plasma Cell | 6 |
| Lymphoma | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Colorectal Neoplasms | 3 |
| Hematologic Neoplasms | 3 |
| Burkitt Lymphoma | 2 |
| Carcinoma, Hepatocellular | 2 |
| Leukemia | 2 |
Trials
Showing 1 to 25 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.